Concepedia

Author

Anna Kondic

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

A Kondic, A. Kondic, A.G. Kondic, Anna G. Kondic, Anna Georgieva Kondic, Anna Kondic, anna kondic

60

Publications

1.2K

Citations

11

H-Index

53

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)University of California, Los AngelesQuantitative BioSciences
AK

About

Anna Kondic is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

591

2

Social Sciences

1

1

12

3

Allergy

1

1

11

4

Biostatistics

1

1

12

5

Cell Biology

1

1

52

Anna Kondic

×

9

Publications

850

Citations

9

H-Index

YearCitations

Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance

David C. Turner, Anna Kondic, Keaven M. Anderson,

Clinical Cancer Research

2018

205

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer

Manash Chatterjee, David C. Turner, Enriqueta Felip,

Annals of Oncology

2016

158

Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors

Malidi Ahamadi, Tomoko Freshwater, Marita Prohn,

CPT Pharmacometrics & Systems Pharmacology

2016

147

Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response

Hongshan Li, Jingyu Yu, Chao Liu,

Journal of Pharmacokinetics and Pharmacodynamics

2017

135

A model-based approach to investigating the pathophysiological mechanisms of hypertension and response to antihypertensive therapies: extending the Guyton model

K. Melissa Hallow, Arthur Lo, Jeni Beh,

American Journal of Physiology-Regulatory, Integrative and Comparative Physiology

2014

76

Immunogenicity of pembrolizumab in patients with advanced tumors

Marianne J.H. van Vugt, Julie A. Stone, “Rik” H. J. M. M. De Greef,

Journal for ImmunoTherapy of Cancer

2019

54

MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis

Robert N. Booher, Harold Hatch, Brian Dolinski,

PLoS ONE

2014

52

Navigating Between Right, Wrong, and Relevant: The Use of Mathematical Modeling in Preclinical Decision Making

Anna Kondic, Dean Bottino, John M. Harrold,

Frontiers in Pharmacology

2022

12

Immunogenicity of pembrolizumab (pembro) in patients (pts) with advanced melanoma (MEL) and non-small cell lung cancer (NSCLC): Pooled results from KEYNOTE-001, 002, 006, and 010.

Marianne van Vugt, Rik de Greef, Tomoko Freshwater,

Journal of Clinical Oncology

2016

11

Page 1